Short Interest in Traws Pharma, Inc. (NASDAQ:TRAW) Declines By 26.0%

Traws Pharma, Inc. (NASDAQ:TRAW) was the target of a large decrease in short interest in November. As of November 30th, there was short interest totalling 7,700 shares, a decrease of 26.0% from the November 15th total of 10,400 shares. Based on an average trading volume of 11,600 shares, the days-to-cover ratio is currently 0.7 days. Currently, 0.3% of the company’s shares are short sold.

Traws Pharma Trading Down 4.5 %

NASDAQ:TRAW traded down $0.22 during trading hours on Friday, hitting $4.62. 3,528 shares of the stock traded hands, compared to its average volume of 5,944. Traws Pharma has a fifty-two week low of $4.06 and a fifty-two week high of $27.50. The firm has a market capitalization of $14.00 million, a price-to-earnings ratio of -0.03 and a beta of 1.46. The business’s 50 day simple moving average is $4.96.

About Traws Pharma

Traws Pharma, Inc, a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.